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355 Family testing: the 17-year experience of Brittany (western
France)
I. Dugue´pe´roux1, V. Scotet1, M.P. Audrezet1,2, M. Blayau3, P. Boisseau4,
P. Parent5, H. Journel6, C. Fe´rec1,2. 1Inserm U 613, Brest, France; 2Dept of
genetics, Brest, France; 3Dept of genetics, Rennes, France; 4Dept of genetics,
Nantes, France; 5Unit of medical genetics, Brest, France; 6Unit of medical
genetics, Vannes, France
In Brittany, extended testing is largely proposed in families of CF patients since
the late 80’s. The aim of this study was to report 17-year experience of family
testing in Brittany and to assess its impact on incidence (period 1989–2005). We
selected, among all the prenatal diagnoses (PDs) performed in women living in
that region over the study period, those performed in couples whose one-in-four
risk was identiﬁed through family testing (46/264, 7.4%). We described the number
of PDs realised, the relationship with the probant, the proportion of CF-fetuses
diagnosed and of consecutive terminations, and assessed the resulting modiﬁcation
in incidence. Over the study period, extended testing in families of CF patients led
to the identiﬁcation of 20 new one-in-four risk couples who opted for PD 40 times
(number per couple: [1–4]). The relationship with the CF child(ren) were: uncle/aunt
(n = 8, 40.0%), sibling (n = 5, 20.0%), cousin (n = 5, 20.0%), niece (n = 1, 5.0%) or
second wife of a father (n = 1–5.0%). A total of 12 CF fetuses were diagnosed, all
of whom were terminated. Family testing is also proposed when an heterozygote
is identiﬁed through newborn screening. This led to detect 5 new one-in-four risk
couples (4 parents and 1 uncle) who opted for PD 6 times. One CF fetus was
identiﬁed and terminated. Overall, these 13 pregnancies terminations represented
16.0% of all the terminations made following a positive PD of CF over that period
(n = 81). This study shows that family testing is largely proposed in Brittany and
contributes to decrease the disease incidence in that region.
Supported by: Association “Vaincre La Mucoviscidose”.
356 Newborn screening (NBS) facilitates diagnosis of previously
unrecognised CF in older siblings
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Introduction: Within the Czech pilot NBS project (2/2005−11/2006) neonatal CF
screening was performed in 76,438 neonates. CF was diagnosed in 12 neonates. 7
of them were ﬁrst born, 5 had older siblings. All of the siblings underwent a sweat
test and 3 of them were diagnosed with CF.
i. NBS CF girl born 4/2005, F508del/G551D CFTR genotype. Her 3-year-old
sister had been followed up since infancy for hepatopathy of unknown ori-
gin. Sweat Cl− 103.2mmol/l together with an identical CFTR genotype and
pancreatic insufﬁciency conﬁrmed CF. Complex treatment led to liver status
normalization and good further progress with only an intermittent S. aureus
airway infection.
ii. NBS CF girl born 3/2006, F508del/I336K CFTR genotype. Her 13-year-old
brother had a history of recurrent respiratory infections. Sweat Cl− 99–96mmol/l
together with an identical CFTR genotype conﬁrmed CF. He was pancreaticly
sufﬁcient. Since complex airway clearance treatment was initiated he has had
no more respiratory problems, a normal FEV1, and only intermitent S. aureus
airway infection.
iii. NBS CF boy born 9/2006, F508del/3849+10kbCT CFTR genotype. His 3-year-
old brother had a history of recurrent respiratory infections. Sweat Cl− 93–
88mmol/l and an identical CFTR genotype conﬁrmed the diagnosis. He was
pancreaticly sufﬁcient. Since complex treatment initiation he has had no more
clinical respiratory problems and only intermitent S. aureus airway infection.
Conclusion: Besides detection of CF in asymptomatic neonates, NBS also helps
diagnose CF in their older siblings whose diagnosis would otherwise have been
made at a much later time.
Supported by: VZ 64203 6405.
357 Survey of the information provided for parents about newborn
screening for CF in European programmes
A. Munck1, A. Duff2, K. Southern3, C. Castellani4, on behalf on the ECFS
CF Neonatal Screening Working Group. 1AFDPHE, Paris, France; 2Teaching
Hospital, Leeds, United Kingdom; 3University, Liverpool, United Kingdom;
4CF Center, Verona, Italy
The ECFS NBS WG provides a forum for CF professionals to produce guidelines
on critical issues and assisting implementing NBS across Europe. A questionnaire
sent to 20 NBS programmes examined the provision of information to (1) all parents
about CF NBS, (2) parents of infants referred to a CF center for further assessment,
(3) parents of infants with CF (positive diagnosis CF NBS), (4) parents of carriers
and (5) parents of non-affected infants (negative NBS).
17 questionnaires (85%) were completed: Austria, France, UK (1 response on
behalf of 5 current programmes), Czech Rep, Spain (4/4), Italy (9/11), Wales (0/1).
Information for (1) provided about the NBS process was similar, usually after birth
(14/17) with a booklet (53%), by a paediatrician (p), nurse (n) or midwife (11, 9,
6); (2) was mainly delivered by phone call (14/17), by the CF p, n, CF geneticist
(g) (7, 6, 2), with a reason of “borderline biological value to be controlled”, CF
was explicitly mentioned in 35%; (3) was provided from a CF p in all cases (plus
a CF g in 41%) given to both parents always, plus the baby in 53% with a booklet
available in 59%; (4) on carrier status (11 programmes include mutation analysis)
was communicated by a CF p or g (9, 7) to both parents (10/11) and DNA testing of
both parents was suggested in 82%. In UK, parents are provided with an information
sheet and support from community nurses; (5) the good health of the baby and
the uselessness of further investigations was emphasized. The results of this survey
suggest some consistent themes across Europe, however there are examples of clear
differences which will be elaborated on, with the presentation of speciﬁc examples.
358* Towards a consensus on the investigation and management of
infants with an equivocal diagnosis following newborn screening
for cystic ﬁbrosis
S.J. Mayell1, A. Munck2, C. Castellani3, J.V. Craig1, K.W. Southern1. 1Child
Health, University of Liverpool, Liverpool, United Kingdom; 2AFDPHE, Paris,
France; 3CF Center, Verona, Italy
Introduction: Newborn screening (NBS) for Cystic Fibrosis (CF) may result in
recognition of infants with an equivocal diagnosis. We employed the Delphi process
to form an international consensus on how to investigate and manage these infants.
Method: 21 statements, composed by a core group, (CC, AM and KWS), were
circulated by email to 80 CF specialists with an interest in this area. For each
statement, the specialist was asked to tick one of 3 options: agree; could agree if
reworded or disagree. Comments were requested. 80% was determined a priori to
be the level of agreement constituting consensus.
Results: 39 responses from CF specialists in 10 European countries have been
received for stage 1. Consensus has been achieved on 10 statements; 7 are
approaching consensus (>60%). 4 statements have a poor level of agreement.
These include guidance on appropriate clinical investigations, the need for further
physiological investigation and appropriate follow up when such tests are normal.
Comments from stage 1 will contribute to achieving consensus following stage 2.
All responders will be invited to contribute to stage 2. They will be provided with
the stage 1 results and a second set of proposed statements.
Conclusion: After a good response, a reasonable level of consensus was achieved
after stage 1. We plan to complete stage 2 by April 2007. The statements should
provide a valuable resource for CF teams with emerging or established NBS
programmes.
